The Indefinite Delivery Contract (IDC) SPE2DM20D9103, awarded by the Defense Logistics Agency (DLA) to Cardinal Health 200, LLC, a subsidiary of Cardinal Health, Inc., aims to provide a wide range of medical and pharmaceutical products to support military treatment facilities and DoD customers in DLA Region 1. The single-award IDC, with a ceiling value of $4,999,999, runs through August 2027 and allows for the rapid procurement of surgical dressings, drugs, biologicals, and other medical consumables under Federal Supply Group 46 and Federal Supply Class 6515. Cardinal Health 200, LLC has also been awarded multiple delivery orders against various IDCs, including SPE2DM20D7009, which has a ceiling value of $4,999,999 and runs through August 2027. These flexible contracting vehicles demonstrate the company's critical role in supporting the federal government's healthcare supply chain, providing essential medical and pharmaceutical products efficiently and at scale to meet the ongoing needs of military and civilian healthcare providers.
In addition to the DLA contracts, Cardinal Health, Inc., the parent company of Cardinal Health 200, LLC, holds a significant Indefinite Delivery Contract (IDV) with the Department of Veterans Affairs Veterans Health Administration, valued at $773,677.24, specifically for the provision of radiopharmaceutical products to support medical imaging procedures within the VA healthcare system. The company's subsidiary, The Harvard Drug Group, L.L.C., has also secured a single-award IDC valued at $10,056,938.10 with the VA National Acquisition Center for the supply of Lurasidone Hydrochloride tablets, further demonstrating Cardinal Health's ability to manage large-scale, multi-agency pharmaceutical supply agreements.
Generated 10/26/24, 9:07 AM